Screening for prostate cancer: The way ahead

BJU International

Volumn 105, Issue 3, 2010, Pages 295-297

  Kirby, Roger S ^a   Eeles, Ros A ^b   Kote Jarai, Zsofia ^b   Guy, Michelle ^b   Easton, Doug ^c   Fitzpatrick, John M ^d  

^a Prostate Centre   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER REGISTRY; CANCER RISK; CANCER SCREENING; CASE CONTROL STUDY; CHROMOSOME 10; CHROMOSOME 11; CHROMOSOME 17; CHROMOSOME 19; CHROMOSOME 3; CHROMOSOME 6; CHROMOSOME 7; CHROMOSOME 8; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; DIAGNOSTIC TEST; GENE MUTATION; GENETIC VARIABILITY; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; NOTE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM; UNITED STATES; X CHROMOSOME;

FORECASTING; HUMANS; MALE; MASS SCREENING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 75149191442     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.09133.x     Document Type: Note

References (12)

1. Schroder F, Hugosson J, Roobol M et al. Screening and prostate cancer mortality in a randomised European study. N Engl J Med 2009 360: 1320 1328
2. Andriole G, Crawford E, Grubb R et al. Mortality Results: from a randomised prostate-cancer screening trial. N Engl J Med 2009 360: 1310 1319
3. Holmstrom B, Johansson M, Bergh A et al. Prostate specific antigen for early detection of prostate cancer: longitudinal study. BMJ 2009 339: b3537
4. Thompson I, Ankerst D, Chi C et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.9 ng/ml or lower JAMA 2005 294: 66 70 (Pubitemid 41002840)
5. Lin D. Beyond PSA: the utility of novel tumour markers in the setting of elevated PSA. Urol Oncol 2009 27: 315 321
6. Kirby RS, Fitzpatrick JM, Irani J. Prostate cancer diagnosis in the new millennium: strengths and weaknesses of prostate-specific antigen and the discovery and clinical evaluation of prostate cancer gene 3 (PCA3). BJU Int 2009 103: 441 445
7. Eeles RA, Kote-Jarai Z, Al Olama AA. Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet 2009 41: 1116 1121
8. Al Olama AA, Kote-Jarai Z, Giles GG et al. Multiple loci on 8q24 associated with prostate cancer susceptibility. Nat Genet 2009 41: 1058 1060
9. Gudmundsson J, Sulem P, Gudbjartsson DF et al. Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility. Nat Genet 2009 41: 1122 1126
10. Yeager M, Chatterjee N, Ciampa J et al. Identification of a new prostate cancer susceptibility fous on chromosome 8q24. Nat Genet 2009 41: 1055 1057
11. Greene KL, Albertsen PC, Babaian RJ et al. Prostate specific antigen best practice statement: 2009 update. J Urol 2009 182: 2232 2241
12. Dasgupta P, Kirby RS. The current status of robot-assisted radical prostatectomy. Asian J Androl 2009 11: 90 3